DelveInsight's, “Primary Sclerosing Cholangitis Pipeline Insight, 2025,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the Primary Sclerosing Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Sclerosing Cholangitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Primary Sclerosing Cholangitis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Primary Sclerosing Cholangitis Pipeline Outlook Report

Key Takeaways from the Primary Sclerosing Cholangitis Pipeline Report

• In June 2025, Ipsen announced a study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug. The trial will also study the study drug's effects on blood tests and other tests related to PSC disease activity.
• In June 2025, Mirum Pharmaceuticals Inc. announced a study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
• In June 2025, NGM Biopharmaceuticals Inc . organized a Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis.
• DelveInsight's Primary Sclerosing Cholangitis pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Primary Sclerosing Cholangitis treatment.
• The leading Primary Sclerosing Cholangitis Companies such as Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
• Promising Primary Sclerosing Cholangitis Pipeline Therapies such as Ritivixibat, HK-660S, Cenicriviroc 150 mg, Elafibranor 80 mg, BTT1023, PLN-74809, Volixibat and others.

Discover how the Primary Sclerosing Cholangitis Treatment paradigm is evolving. Access DelveInsight's in-depth Primary Sclerosing Cholangitis Pipeline Analysis for a closer look at promising breakthroughs @ Primary Sclerosing Cholangitis Clinical Trials and Studies

Primary Sclerosing Cholangitis Emerging Drugs Profile

• GS-9674: Gilead Sciences

GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.

• IMU-838: Immunic

IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment PSC. The drug is in clinical studies for the treatment of Relapsing-Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Crohn's Disease, and Primary Sclerosing Cholangitis. The drug is in Phase II clinical studies for the treatment of Primary sclerosing cholangitis.

The Primary Sclerosing Cholangitis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
• Primary Sclerosing Cholangitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market

Explore groundbreaking therapies and clinical trials in the Primary Sclerosing Cholangitis Pipeline. Access DelveInsight's detailed report now! @ New Primary Sclerosing Cholangitis Drugs

Primary Sclerosing Cholangitis Companies

Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.

Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Primary Sclerosing Cholangitis Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Primary Sclerosing Cholangitis Market Drivers and Barriers, and Future Perspectives

Scope of the Primary Sclerosing Cholangitis Pipeline Report

• Coverage- Global
• Primary Sclerosing Cholangitis Companies- Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
• Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, HK-660S, Cenicriviroc 150 mg, Elafibranor 80 mg, BTT1023, PLN-74809, Volixibat and others.
• Primary Sclerosing Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Primary Sclerosing Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Primary Sclerosing Cholangitis Drug development? Find out in DelveInsight's exclusive Primary Sclerosing Cholangitis Pipeline Report-access it now! @ Primary Sclerosing Cholangitis Emerging Drugs and Major Companies

Table of Contents